BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX opened at $0.11 on Friday. The company has a market capitalization of $8.39 million, a price-to-earnings ratio of -0.48 and a beta of 1.46. BioLineRx has a 52-week low of $0.08 and a 52-week high of $1.44. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The stock has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.48.

BioLineRx shares are set to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Research analysts predict that BioLineRx will post -0.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BLRX. CVI Holdings LLC acquired a new stake in shares of BioLineRx during the second quarter worth about $462,000. Atria Investments Inc raised its stake in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new stake in BioLineRx during the 2nd quarter worth approximately $70,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.